The accelerated FDA approval for Jemperli in advanced rectal cancer is expected to intensify competition across colorectal settings where checkpoint inhibitors are being expanded beyond traditional disease boundaries. Even without efficacy numbers in the release text, the label action confirms a regulatory pathway that relies on biomarker-defined patient selection. This is the latest example of how manufacturers and biotech pipelines are built around genetic signatures that can unlock faster regulatory updates. It also creates a sequencing challenge for clinicians deciding between newly approved strategies and evolving combination regimens. For biotech strategists, the key operational point is to map how biomarker criteria and prior-line treatment definitions align across trials, as differences can determine real-world eligibility and uptake.